플러스100%마이너스

통합검색
닫기

KMCRIC 챗봇에게

질문하기!

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms.

Authors

Cornu C, Mercier C, Ginhoux T, Masson S, Mouchet J, Nony P, Kassai B, Laudy V, Berquin P, Franc N, Le Heuzey MF, Desombre H, Revol O.

Journal

Eur Child Adolesc Psychiatry.

Year

2018

Vol (Issue)

27(3)

Page

377-84.

doi

10.1007/s00787-017-1058-z.

PMID

28993963

Url

http://www.ncbi.nlm.nih.gov/pubmed/28993963

MeSH

Adolescent
Attention Deficit Disorder with Hyperactivity/drug therapy*
Child
Double-Blind Method
Fatty Acids, Omega-3/pharmacology
Fatty Acids, Omega-3/therapeutic use*
Female
Humans
Male
Treatment Outcome

Keywords

Child ADHD; Omega-3 rich fatty acid supplementation; Randomized controlled trial

한글 키워드

어린이 ADHD; 오메가-3 지방산 보충제; 무작위배정 비교 임상시험

KMCRIC
Summary & Commentary

KMCRIC 비평 보기 +

Korean Study

Abstract

OBJECTIVE:
Clinical trials and inconclusive meta-analyses have investigated the effects of omega-3 supplements in children with Attention-Deficit Hyperactivity Disorder (ADHD). We performed a randomised placebo-controlled trial to evaluate the efficacy of omega-3 fatty acids.

METHODS:
Children aged 6-15 years with established diagnosis of ADHD were randomised 1:1 to receive either supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) or a placebo for 3 months. Psychotropic or omega-3-containing treatments were not authorised during the study. The primary outcome was the change in the Attention-Deficit Hyperactivity Disorder Rating Scale version 4 (ADHD-RS-IV). Other outcomes included safety, lexical level (Alouette test), attention (Test of Attentional Performance for Children-KiTAP), anxiety (48-item Conners Parent Rating Scale-Revised-CPRS-R), and depression (Children's Depression Inventory-CDI).

RESULTS:
Between 2009 and 2011, 162 children were included in five French child psychiatry centres. The mean age was 9.90 (SD 2.62) years and 78.4% were boys. The inclusion ADHD-RS-IV at was 37.31 (SD 8.40). The total ADHD-RS-IV score reduction was greater in the placebo group than in the DHA-EPA group: -19 (-26, -12) % and -9.7 (-16.6, -2.9) %, respectively, p = 0.039. The other components of the Conners score had a similar variation but the differences between groups were not significant. Two patients in the DHA-EPA group and none in the placebo group experienced a severe adverse event (hospitalisation for worsening ADHD symptoms).

CONCLUSION:
This study did not show any beneficial effect of omega-3 supplement in children with mild ADHD symptoms.

국문초록

Language

영어

첨부파일